Brandon Weckbaugh, MD, an oncology fellow at the University of Missouri-Kansas City, discusses the results of the LIBRETTO-001 trial in the patients with non–small cell small cancer (NSCLC).
Brandon Weckbaugh, MD
Advertisement
Articles by Brandon Weckbaugh, MD
Advertisement
Latest Updated Articles
Dr. Weckbaugh on the LIBRETTO-001 Trial in NSCLCPublished: April 4th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5